Heterocyclic Factor IXa Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for factor IXa, a key enzyme in the blood coagulation cascade, which is crucial for preventing thromboembolic disorders such as acute coronary syndrome and atherosclerosis.
Innovation Solution
Development of novel heterocyclic compounds that selectively inhibit factor IXa, which can be formulated into pharmaceutical compositions for treating or preventing thromboembolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If factor IXa inhibitors are developed to treat thromboembolic disorders, then therapeutic effectiveness is improved, but safety and selectivity challenges worsen
Solution Approach 1:
The patent applies local quality by designing factor IXa inhibitors with specific molecular structures (heterocyclic compounds with defined substituents and stereochemistry) that provide selective binding to factor IXa. The invention specifies particular chemical moieties and spatial arrangements that enable selective inhibition at the factor IXa active site, thereby achieving therapeutic effectiveness while minimizing off-target effects and enhancing safety profile.
2Reliability
If selective factor IXa inhibitors are designed, then therapeutic specificity is improved, but compound complexity worsens
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core heterocyclic structure (such as pyridine, pyrimidine, or triazole rings) and specific substituent groups (e.g., aryl, alkyl, or heteroaryl groups at defined positions). This modular approach allows for systematic variation of substituents to optimize selectivity while maintaining manageable structural complexity through standardized building blocks.
Solution Approach 2:
The patent applies parameter changes by systematically varying molecular parameters such as substituent types, steric configurations, and electronic properties of the heterocyclic core to achieve optimal selectivity. The invention explores different heterocyclic cores, substitution patterns, and stereochemical configurations to fine-tune the binding affinity and specificity of factor IXa inhibitors.
Data Source
AI summary
The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.